# OnCo record melanoma-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/melanoma-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "melanoma-signalling" ;
  schema:name "Melanoma (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05218"@en, "Melanoma"@en ;
  schema:description "KEGG's melanoma map shows BRAF or NRAS mutations driving the MAPK growth relay, PTEN loss driving PI3K/AKT, and loss of the CDKN2A brakes (p16 and p14ARF) on CDK4/6 and p53. BRAF plus MEK inhibitors and immune checkpoint antibodies have transformed treatment."@en ;
  schema:url <https://onco.cc/pathways/melanoma-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05218>, <https://doi.org/10.1038/nrc.2016.37> ;
  onco:related <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/mdm2/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/cobimetinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/cell-cycle-engine-cdks/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-shain-nat-rev-cancer/> .